BUZZ-Coeptis rises on licensing agreement to develop cancer cell therapies

Reuters
03-11
BUZZ-Coeptis rises on licensing agreement to develop cancer cell therapies

** Cancer therapy developer Coeptis Therapeutics' COEP.O shares rise 2.3% to $11.15

** Co says it has licensed worldwide development and commercialization rights to cell therapy platform GEAR

** As part of the agreement with VyGen-Bio, Coeptis has formed a new majority-owned subsidiary, GEAR Therapeutics, to advance applications of the technology

** GEAR (Gene Edited Antibody Resistant) cell therapy platform modifies immune cells to effectively target and destroy cancer cells without being neutralized by antibodies taken during treatment

** Up to last close, COEP has risen 13.5% in the past 12 months

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10